Cargando…

Construction of IL-13 Receptor α2-Targeting Resveratrol Nanoparticles against Glioblastoma Cells: Therapeutic Efficacy and Molecular Effects

Glioblastoma multiforme (GBM) is the most common lethal primary brain malignancy without reliable therapeutic drugs. IL-13Rα2 is frequently expressed in GBMs as a molecular marker. Resveratrol (Res) effectively inhibits GBM cell growth but has not been applied in vivo because of its low brain bioava...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Xiao-Min, Shi, Xiao-Xiao, Xiong, Le, Nie, Jun-Hua, Ye, Hai-Shan, Du, Jin-Zi, Liu, Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508707/ https://www.ncbi.nlm.nih.gov/pubmed/34638961 http://dx.doi.org/10.3390/ijms221910622

Ejemplares similares

Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo
por: Xiong, Le, et al.
Publicado: (2021)

Differential Exosomic Proteomic Patterns and Their Influence in Resveratrol Sensitivities of Glioblastoma Cells
por: Nie, Jun-Hua, et al.
Publicado: (2019)

Metabolic Patterns and Biotransformation Activities of Resveratrol in Human Glioblastoma Cells: Relevance with Therapeutic Efficacies
por: Shu, Xiao-Hong, et al.
Publicado: (2011)

Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel
por: Wang, Baoyan, et al.
Publicado: (2015)

Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers
por: Liang, Ruijia, et al.
Publicado: (2022)

IL-13Rα2 humanized scFv-based CAR-T cells exhibit therapeutic activity against glioblastoma
por: Xu, Chang, et al.
Publicado: (2022)

Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex
por: Tollenaere, Maxim A.X., et al.
Publicado: (2023)

Postoperative resveratrol administration improves prognosis of rat orthotopic glioblastomas
por: Song, Xue, et al.
Publicado: (2018)

Clinical development of IL13Rα2-targeting CAR T cells for the treatment of glioblastoma
por: Brown, Christine E, et al.
Publicado: (2015)

Resveratrol as a potential therapeutic drug for respiratory system diseases
por: Zhu, Xiao-dan, et al.
Publicado: (2017)

Glioblastoma-on-a-chip construction and therapeutic applications
por: Xie, Zuorun, et al.
Publicado: (2023)

Synergistic Effects of Resveratrol and Temozolomide Against Glioblastoma Cells: Underlying Mechanism and Therapeutic Implications
por: Liu, Yusi, et al.
Publicado: (2020)

IL-13 receptors as possible therapeutic targets in diffuse intrinsic pontine glioma
por: Berlow, Noah E., et al.
Publicado: (2018)

Increased Reactive Oxygen Species and Distinct Oxidative Damage in Resveratrol-suppressed Glioblastoma Cells
por: Jia, Bin, et al.
Publicado: (2021)

Therapeutic potentials of resveratrol in combination with radiotherapy and chemotherapy during glioblastoma treatment: a mechanistic review
por: Arabzadeh, AmirAhmad, et al.
Publicado: (2021)

Enhanced Interleukin (IL)-13 Responses in Mice Lacking IL-13 Receptor α 2
por: Wood, Nancy, et al.
Publicado: (2003)

IL-13Rα2 Glycosylation Holds the Dance Card for Partnering with IL-13
por: Dy, Alane B. C., et al.
Publicado: (2020)

Effects of resveratrol and genistein on nuclear factor-κB, tumor necrosis factor-α and matrix metalloproteinase-9 in patients with chronic obstructive pulmonary disease
por: LIU, XIAO-JU, et al.
Publicado: (2016)

A novel TanCAR targeting IL13Rα2 and EphA2 for enhanced glioblastoma therapy
por: Muhammad, Niaz, et al.
Publicado: (2022)

Resveratrol as a Therapeutic Agent for Alzheimer's Disease
por: Ma, Teng, et al.
Publicado: (2014)

Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses
por: He, Xuan, et al.
Publicado: (2023)

Biological implications of PTEN upregulation and altered sodium/iodide symporter intracellular distribution in resveratrol-suppressed anaplastic thyroid cancer cells
por: Xiong, Le, et al.
Publicado: (2020)

The Proteomic and Genomic Teratogenicity Elicited by Valproic Acid Is Preventable with Resveratrol and α-Tocopherol
por: Chen, Yeh, et al.
Publicado: (2014)

Tuning sensitivity to IL-4 and IL-13: differential expression of IL-4Rα, IL-13Rα1, and γc regulates relative cytokine sensitivity
por: Junttila, Ilkka S., et al.
Publicado: (2008)

IL13RA2 targeted alpha particle therapy against glioblastomas
por: Sattiraju, Anirudh, et al.
Publicado: (2017)

Lumbar puncture-administered resveratrol inhibits STAT3 activation, enhancing autophagy and apoptosis in orthotopic rat glioblastomas
por: Xue, Song, et al.
Publicado: (2016)

An IL13Rα2 peptide exhibits therapeutic activity against metastatic colorectal cancer
por: Bartolomé, Rubén A., et al.
Publicado: (2018)

IL-13Rα2 Is a Biomarker of Diagnosis and Therapeutic Response in Human Pancreatic Cancer
por: Fujisawa, Toshio, et al.
Publicado: (2021)

Adoptive transfer of IL13Rα2-specific T cells for the treatment of glioblastoma: building on clinical achievements with second-generation CARs
por: Brown, Christine E, et al.
Publicado: (2013)

Identification of a novel role of IL-13Rα2 in human Glioblastoma multiforme: interleukin-13 mediates signal transduction through AP-1 pathway
por: Bhardwaj, Rukmini, et al.
Publicado: (2018)

Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes
por: Ulzii, Dugarmaa, et al.
Publicado: (2019)

Resveratrol-modified mesoporous silica nanoparticle for tumor-targeted therapy of gastric cancer
por: Lin, Mingzhen, et al.
Publicado: (2021)

Resveratrol extracted from Chinese herbal medicines: A novel therapeutic strategy for lung diseases
por: Ma, Bo-ning, et al.
Publicado: (2020)

Therapeutic Versatility of Resveratrol Derivatives
por: Nawaz, Waqas, et al.
Publicado: (2017)

IL4Rα and IL13Rα1 Are Involved in the Development of Human Gallbladder Cancer
por: Ahn, Sung Woo, et al.
Publicado: (2022)

IGFBP2 is a potential biomarker in acute kidney injury (AKI) and resveratrol-loaded nanoparticles prevent AKI
por: Li, Hai-Lun, et al.
Publicado: (2018)

Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma
por: Schmidts, Andrea, et al.
Publicado: (2022)

IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma
por: Nur Husna, Siti Muhamad, et al.
Publicado: (2022)

Engineered IL13 variants direct specificity of IL13Rα2-targeted CAR T cell therapy
por: Stern, Lawrence A., et al.
Publicado: (2022)

The IL-13/IL-4Rα axis is involved in tuberculosis-associated pathology
por: Heitmann, Lisa, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1ljnbu8kcnens4f04uk8k9f0ab